Welcome to our dedicated page for ERPY news (Ticker: ERPY), a resource for investors and traders seeking the latest updates and insights on ERPY stock.
ERP Technologies (ERPY) provides investors and business professionals with essential updates through this comprehensive news hub. Track official announcements including financial disclosures, product enhancements, and strategic collaborations that shape this ERP innovator's market position.
Access timely updates on earnings reports, operational milestones, and partnership developments like ERPY's collaboration with Vetophage. Our curated feed ensures you never miss critical information about software innovations or industry leadership changes.
Discover verified information about enterprise solution developments directly from primary sources. This resource serves both technical professionals seeking product details and investors monitoring organizational growth patterns.
Bookmark this page for streamlined access to ERPY's evolving business narrative. Regular updates ensure you maintain informed perspectives on this dynamic player in enterprise resource planning technology.
ERYTECH Pharma announced its transfer of American Depositary Shares (ADSs) from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective April 14, 2023. This decision follows approval from The Nasdaq Stock Market, based on the company's compliance with market value requirements, except for the bid price criterion. ERYTECH has been granted an additional 180 days to meet the bid price of $1.00 per share for ten consecutive business days. The company will effect a reverse stock split if necessary. Despite the transfer, trading under the symbol ERYP remains unaffected. ERYTECH develops therapies for severe cancer and orphan diseases using its ERYCAPS platform, creating innovative drug encapsulation technologies.
Monthly Information on Voting Rights and Share Capital as of March 31, 2023
The press release details the current total number of shares and voting rights for ERYP, listed on Euronext Paris and Nasdaq. As of March 31, 2023, the total number of shares is 31,018,553. The total gross voting rights stand at 32,521,652, while the total net voting rights are 32,519,152. This information complies with Article 223-16 of the French financial market regulations, aimed at providing shareholders with transparency regarding voting rights.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) has provided a business and financial update for Q4 and the full year of 2022. The company announced a strategic combination with Pherecydes to lead in extended phage therapies against antimicrobial-resistant bacteria. Notably, ERYTECH sold its U.S. cell therapy manufacturing facility for $44.5 million and executed a significant restructuring, reducing staff by 75%. Ending December 2022, cash and cash equivalents stood at €38.8 million ($41.5 million). Despite halting its Graspa® program, the company aims to fund existing operations into Q3 2024, supported by strategic decision-making and partnerships.
Erytech Pharma has released its monthly update on the total number of voting rights and shares as of February 28, 2023. The company has a total of 31,018,553 shares composing the share capital. The gross voting rights number has been reported as 32,516,875, while the net voting rights stand at 32,514,375. These figures indicate a slight decrease in net voting rights compared to the previous month, reflecting ongoing adjustments in share structure.
The company is listed on both Euronext Paris and the Nasdaq Global Select Market, with the symbol ERPY.
